For $75M up front, Biogen will pursue Pfizer castoff for circadian rhythm in AD, PD

Biogen to evaluate Pfizer asset to normalize circadian rhythm-associated Alzheimer’s, Parkinson’s symptoms

By Elizabeth S. Eaton, Staff Writer | Jan 13, 2020 | 10:16 PM GMT
Editor's note: Updated on Jan 17, 2020 at 10:10 PM GMT

Biogen acquired a clinical asset from Pfizer and will investigate its potential to normalize circadian rhythm to treat “sundowning” in Alzheimer’s disease and irregular sleep associated with Parkinson’s disease.

Monday’s deal is

Read the full 314 word article

How to gain access

Continue reading with a
two-week free trial.